This report describes the design and synthesis of a series of a V b 3 integrin-directed monomeric, dimeric and tetrameric cyclo[Arg-Gly-Asp-D-Phe-Lys] dendrimers using "click chemistry". It was found that the unprotected N-e-azido derivative of cyclo[Arg-Gly-Asp-D-Phe-Lys] underwent a highly chemoselective conjugation to amino acid-based dendrimers bearing terminal alkynes using a microwave-assisted Cu(I)-catalyzed 1,3-dipolar cycloaddition. The a V b 3 binding characteristics of the dendrimers were determined in vitro and their in vivo a V b 3 targeting properties were assessed in nude mice with subcutaneously growing human SK-RC-52 tumors. The multivalent RGD-dendrimers were found to have enhanced affinity toward the a V b 3 integrin receptor as compared to the monomeric derivative as determined in an in vitro binding assay. In case of the DOTA-conjugated 111 In-labeled RGD-dendrimers, it was found that the radiolabeled multimeric dendrimers showed specifically enhanced uptake in a V b 3 integrin expressing tumors in vivo. These studies showed that the tetrameric RGD-dendrimer had better tumor targeting properties than its dimeric and monomeric congeners. Several peptidic 5 and peptidomimetic 6 a V b 3 antagonists have been synthesized. Among these, the cyclo[Arg-Gly-Asp-D-Phe-Val] (c[RGDfV]), as developed by Kessler and coworkers, is one of the most active and selective antagonists for the a V b 3 integrin. 7 Scheme 1 Synthesis of the mono-, di-and tetravalent dendrimeric alkynes 2, 3 and 7.
Introduction
Integrins are a class of heterodimeric transmembrane proteins 1 which play an important role in cell-signaling, cell-cell adhesion, apoptosis and cell-matrix interactions. 2 Integrin a V b 3 , which binds to the Arg-Gly-Asp (RGD) tripeptide motif containing ligands, 3 plays a pivotal role in tumor angiogenesis 2 and metastasis. a V b 3 Integrin expressed on endothelial cells modulate cell migration and survival during angiogenesis, while a V b 3 integrin expressed on carcinoma cells potentiate metastasis by facilitating invasion and movement across blood vessels. The a V b 3 integrin is expressed on activated endothelial cells during tumor induced angiogenesis, whereas it is absent on quiescent endothelial cells and normal tissues. In addition, a V b 3 is expressed on various tumor cell types (e.g. breast, ovarian, and prostate cancers) . Evidence exists that inhibition of a V b 3 integrin function prevents tumor growth and induces tumor regression by antagonizing angiogenesis. 4 Structure-activity relationship studies on this cyclic pentapeptide showed that the exchange of the valine by a lysine residue (Lys, K) did not significantly influence activity and selectivity. 8 Because the e-amino moiety of the lysine residue can be easily modified, numerous applications of c [RGDfK] have been studied for tumor targeting and imaging. 9 Multivalency is a well accepted approach to increase the interaction of weakly interacting individual ligands with their respective receptors. 10 Dendrimers are macromolecules consisting of multiple perfectly branched monomers and this architecture makes them versatile constructs for the simultaneous presentation of receptor binding ligands and other biologically relevant molecules. 11 Additionally, dendrimers might serve as promising molecular scaffolds containing a number of ligands thereby inducing an apparent increase of ligand concentration and increasing the probability of statistical rebinding. 10b-e, 12 Alternatively, dendrimers may align these ligands and induce multivalency when receptor clustering occurs or is initiated after initial monovalent binding. 10b-e To improve tumor targeting efficacy and to obtain better in vivo imaging properties, several studies explored the multivalency effect by using dimeric and tetrameric RGD peptides with affinity toward the a V b 3 integrin. 13 These studies clearly demonstrated the multivalency effect, since the in vivo affinity significantly increased going from monomer via dimer to tetramer. Moreover, also with respect to tumor-uptake and tumor-to-organ ratios, a similar increase was observed. These are promising results in view of the development of integrin-targeted radionuclide therapy. 12 To decorate the dendrimer end-groups with biologically relevant peptides as ligands, it is of crucial importance to have the disposal of efficient and chemoselective conjugation chemistry to ensure the complete attachment of the ligands to the dendrimer. In cases of completely amino acid-or peptide-based dendrimers, 14,15 this is often achieved using peptide coupling reagents, however, in most cases, the peptide ligands are attached to dendrimers by chemoselective reaction of sulfhydryl groups of cysteine residues with maleimide or iodoacetamide functionalities, 16 by thiol-disulfide exchange, by native chemical ligation 17 or via a chemoselective oxime 13d-l,m respectively hydrazone 18 ligation. However, new bioconjugation reactions with mutually reactive conjugation partners with increased efficiency and chemoselectivity which are synthetically easily accessible would be very welcome.
Recently, the well-known reaction between an alkyne and an azide to yield 1,4-disubstituted 1,2,3-triazoles, was reinvestigated independently by Meldal et al. 19a and Sharpless et al. 19b They found that an alkyne and an azide in the presence of Cu(I) undergo a 1,3-dipolar cycloaddition to the corresponding triazole under very mild reaction conditions with very high chemoselectivity and efficiency which make this reaction particularly suitable for bioconjugations. So far, this 1,3-dipolar cycloaddition denoted as a 'click reaction', 20 has led to a plethora of applications in the literature. 21 Recently, we synthesized multivalent dendrimeric peptides 22a (up to octa-and hexadecavalent systems) respectively triazole-linked glycodendrimers 22b via a microwave-assisted 1,3dipolar cycloaddition between azido peptides respectively glycosyl azides and dendrimeric alkynes as an alternative approach to functionalize dendrimers. 22c Here we describe the synthesis of monomeric, dimeric and tetrameric c[RGDfK] dendrimers via a microwave-assisted 1,3dipolar cycloaddition of dendrimeric alkynes with the N-e-azido derivative of cyclo[Arg-Gly-Asp-D-Phe-Lys] and their subsequent evaluation as a V b 3 integrin antagonists. Additionally, the RGD dendrimers were conjugated with a 1, 4, 7, N , N , moiety. These analogs were radiolabeled with 111 In to evaluate the in vitro receptor binding characteristics and in vivo tumor targeting properties.
Results and discussion

Synthesis
Schemes 1 and 2 illustrate our approach for the convergent synthesis of amino acid based dendrimers 23 and their corresponding DOTA-conjugated derivatives. Monovalent compound 2 and divalent 3 respectively, were synthesized starting from 3hydroxy methyl benzoate or 3,5-dihydroxy methyl benzoate and propargylbromide in the presence of K 2 CO 3 as a base and were obtained in 95 and 81% yield. Since these two compounds were also used as synthons in further syntheses, the resulting methyl esters 2 and 3 were treated with Tesser's base 24 to yield acids 4 and 5 in nearly quantitative yield. After treatment of the previously described 6 23c with TFA to remove both Boc-functionalities, the resulting bisamine TFA salt was coupled to acid 5 in the presence of BOP-DIPEA to give the tetravalent dendrimer 7 with 75% yield. To conjugate the tetravalent dendrimer with a DOTA-moiety at a later stage of the synthesis, its methyl ester was saponified with Tesser's base and acid 8 was obtained quantitatively.
The DOTA-moiety was connected to the dendrimer core via a short ethylene spacer. For this purpose, 1,2-diaminoethane was converted into the mono-protected Boc derivative 10 which was obtained in 56% yield. Unfortunately, although a large excess of the amine was used, the bis-protected side product was obtained in a considerable amount. Compound 10 was coupled in the presence of BOP-DIPEA to either the monovalent, divalent or tetravalent dendrimer acids 4, 5 or 8 to obtain the corresponding amides 11, 12 or 15, respectively, generally in yields higher than 90%. The Boc-protected dendrimers were treated with TFA to obtain the corresponding amines and they were treated with BOP-DIPEA in the presence of 2-(4,7,10-tris(2-tert-butoxy-2-oxoethyl)-1,4,7,10tetraazacyclododecan-1-yl) acetic acid (DOTA(O t Bu) 3 ) to give the DOTA-conjugated mono-, di-and tetravalent dendrimers 13, 14 Scheme 2 Synthesis of the DOTA-conjugated dendrimeric alkynes 13, 14 and 16. and 16 respectively. It is important to note that the solubility of the DOTA-conjugated dendrimer is an important factor that determines the yield of the coupling reaction. Compounds 13 and 14 were isolated in very high yields (>94%) but compound 16 was isolated with a modest yield of 60% due to its low solubility in solvents like EtOAc and CH 2 Cl 2 .
The next step in the synthesis was the preparation of the Ne-azido cyclo(Arg-Gly-Asp-D-Phe-Lys) peptide 19 (Scheme 3). To obtain this compound, peptide resin 17 was synthesized using Fmoc-t Bu SPPS (solid phase peptide synthesis) based on the protocol of Liu et al. 25 It was decided to cleave the protected peptide acid from the resin by HFIP-CH 2 Cl 2 26 instead of AcOH-TFE to avoid premature acetylation during the BOP-DIPEA-mediated macrolactamization step. Cyclic peptide 18 was obtained in 36% overall yield based on the initial resin loading of 0.64 mmol g −1 . Subsequently, the e-amine of the lysine residue was selectively converted into the azide moiety by a diazotransfer. 27 At pH 10, the e-amine can be deprotonated in the presence of a guanidino functionality, since the latter is a much stronger base and will not act as a nucleophile in the diazotransfer reaction. Finally, the peptide N-e-azido cyclo(Arg-Gly-Asp-D-Phe-Lys) 19 was obtained in 21% yield after purification by HPLC and was characterized by 1 H-NMR (500 MHz) and mass spectrometry (LC-MS). Incorporation of Fmoc-Lys(N 3 )-OH, to avoid the diazo transfer as the final reaction step, did not substantially improve the isolated yield.
At this stage of the synthesis, the challenge was the chemoselective coupling of the different dendrimeric alkynes (2, 3, 7, 13, 14, or 16) to the cyclic RGD azido peptide (19) to furnish the DOTA-conjugated dendrimeric cyclo-RGD peptides as a V b 3 integrin antagonists as shown in Scheme 4. Our first experiments were based on the literature procedure 19b in which acetylene 3 was coupled to azido glycine ethyl ester (ethyl 2-azidoacetate) in the presence of CuSO 4 -Na-ascorbate-Cu-wire in tert-BuOH-H 2 O for 16 h at room temperature. Monitoring the reaction by TLC showed that formation of the monovalent cycloadduct proceeded rapidly, but the conversion into the divalent product was sluggish. However, a tremendous improvement was achieved by running this reaction under microwave irradiation. After 10 min at 100 • C using DMF-H 2 O as solvent in the presence of CuSO 4 -Na-ascorbate, the divalent cycloaddition product was obtained in 96% yield. This microwave-assisted cycloaddition of dendrimeric alkynes and azido peptides was recently reported as a versatile approach to obtain multivalent dendrimeric peptides. 22a,c The optimized reaction conditions were used to couple the cyclic RGD azido peptide (19) to the different dendrimeric alkynes (2, 3, 7, 13, 14, or 16).
In case of alkynes 2, 3 and 7 the formation of the cycloadducts 20, 21 and 22 could be followed by TLC and LC-MS. It turned out that the formation of 20 and 21 was complete after 10 to 20 min microwave irradiation at 100 • C, whereas the formation of 22 was complete after 30 min. Although HPLC analysis of the crude cycloaddition products evidenced a complete conversion as judged by the absence of the alkyne starting material, the RGDdendrimers 20-22 were obtained in yields varying between 14 to 57%. Then, the DOTA-conjugated alkyne dendrimers 13, 14 and 16 were subjected to the cycloaddition reaction conditions in the presence of azido peptide 19. It should be emphasized that the carboxyl functionalities of the DOTA-moiety needed to be protected by tert-butyl groups to avoid premature and irreversible sequestering of the Cu 2+ ions. Chelated copper(II) will result in a lower efficiency of the Cu(II)-Cu(I) redox couple to generate the active Cu(I)-catalyst. More importantly, it will hamper the radiolabeling of the DOTA-moiety of compounds 23-25 with trivalent radiometals such as 111 In, 90 Y or 177 Lu. As a result, after the click reaction an additional reaction step was needed in which the partially protected cycloadducts were treated with TFA, in the presence of suitable scavengers, to give the unprotected DOTAconjugated RGD-dendrimers 23-25.
The cycloaddition reaction of the DOTA-conjugated dendrimeric alkynes 13, 14 and 16 was difficult to monitor by mass spectrometry. As was described above, reaction times of 10 to 30 min were used and the cycloaddition reaction was directly followed by a TFA-treatment without isolation of the cycloaddition intermediates. The isolated yield (13%) of monovalent 23 was rather disappointing. Recently, optimized conditions with respect to the generation of the catalytic active Cu(I) species were published 28 and these conditions were applied in the cycloaddition of 14 and 19. Unfortunately, an increase of the isolated yield was not observed using these modified reaction conditions. As was mentioned earlier, the cycloaddition reaction was complete according to HPLC analysis, and the low isolated yield was mainly due to the difficult purification. The DOTA-conjugated RGDdendrimers were obtained in yields varying between 11 and 36%. 
Solid phase a V b 3 binding assay
The affinity of the DOTA-conjugated RGD dendrimers 23, 24, and 25 for the a v b 3 integrin was determined in a competitive binding assay. The results of these analyses are shown in Fig. 1 . Binding of the 111 In-labeled dimeric peptide, 111 In-DOTA-Glu-(c[RGDfK]) 2 , 29 to a v b 3 was competed by unlabeled 23, 24, and 25 in a concentration dependent manner. The IC 50 values were 212 nM for monovalent 23, 356 nM for divalent 24, and 50 nM for (25) showed an increased affinity for a v b 3 compared to the dendrimers containing one (23) or two (24) 
Biodistribution studies
In athymic mice with subcutaneously (s.c.) growing SK-RC-52 renal cell carcinoma, the tumor uptake of the 111 In-labeled tetrameric RGD dendrimer 25 at 2 h post-injection (p.i.; 7.27 ± 2.06%ID/g) was significantly higher (P < 0.05) compared to that of the 111 In-labeled monomeric RGD dendrimer 23 (1.69 ± 0.41%ID/g) as shown in Fig. 2A . At 2 h p.i., the tumor uptake of tetrameric RGD dendrimer 25 was also significantly higher (P < 0.05) than the dimeric analog 24 (3.15 ± 0.51%ID/g). The tumor-to-blood ratios of the tetramer 25 (5.66 ± 1.74%ID/g, 34.73 ± 5.95%ID/g) were significantly higher (P < 0.05)-both at 2 h p.i. and at 24 h p.i.-than those of the monomer 23 (3.12 ± 1.92%ID/g, 19.65 ± 12.42%ID/g) and dimer 24 (1.70 ± 0.50%ID/g, 14.66 ± 0.25%ID/g). At 24 h post injection, the tumor uptake of the tetrameric RGD dendrimer 25 (5.83 ± 1.18%ID/g) was significantly higher compared to the dimeric RGD dendrimer 24 (2.82 ± 0.59%ID/g, P < 0.05) and the monomeric RGD dendrimer 23 (1.19 ± 0.31%ID/g, P < 0.01) which is shown in Fig. 2B . Co-injection of an excess of non-radiolabeled RGD peptide (DOTA-Glu- (c[RGDfK] ) 2 ) to saturate all a v b 3 receptors in vivo, resulted in a significantly reduced tumor uptake of each of the three compounds: 23: 0.46 ± 0.04%ID/g (2 h p.i.), 0.36 ± 0.31%ID/g (24 h p.i.), 24: 0.76 ± 0.09%ID/g (2 h p.i.), not determined (24 h p.i.) and 24: 1.56 ± 0.02%ID/g (2 h p.i.), 1.19 ± 0.03%ID/g (24 h p.i.), indicating that each of the three RGD dendrimers of this study showed receptor mediated uptake in the tumor. These in vivo results were in line with the in vitro binding assay. The tetrameric RGD dendrimer showed enhanced affinity for a v b 3 , as compared to the monomeric and dimeric RGD dendrimer, respectively. The results of this study correlated nicely with the results observed in a previous study in which we evaluated multimeric RGD peptides in the same animal model. 13o
The affinity of the dendrimers as determined in an in vitro binding assay are in agreement with the results obtained from the in vivo experiment: the IC 50 concentration of the tetrameric RGD dendrimer 25 was lower compared to those of the monomeric 23 and dimeric 24 analogs, resulting in a significantly higher uptake of the former in a v b 3 -expressing tumors and better tumor-to-blood ratios compared to the monomeric and dimeric RGD dendrimers.
In conclusion, a series of a V b 3 integrin-directed monomeric, dimeric and tetrameric cyclo[Arg-Gly-Asp-D-Phe-Lys] dendrimers using "click chemistry" was successfully synthesized, since the unprotected N-e-azido derivative of cyclo[Arg-Gly-Asp-D-Phe-Lys] underwent a highly chemoselective conjugation to amino acidbased dendrimers bearing terminal alkynes using a microwaveassisted Cu(I)-catalyzed 1,3-dipolar cycloaddition. The a V b 3 binding characteristics and a V b 3 targeting properties of the dendrimers were determined both in vitro and in vivo. In the case of the DOTAconjugated 111 In-labeled RGD-dendrimers, it was found that the radiolabeled multimeric dendrimers showed specifically enhanced uptake in a V b 3 integrin expressing tumors in vivo. These studies showed that the tetrameric RGD-dendrimer had better tumor targeting properties than its dimeric and monomeric congeners.
Experimental
Instruments and methods
Peptides were synthesized on an ABI 433A automatic Peptide Synthesizer using the FastMoc solid phase peptide synthesis protocols. Microwave-assisted reactions were carried out in a Biotage microwave reactor. Analytical HPLC runs were carried out on a Shimadzu HPLC system and preparative HPLC runs were performed on a Gilson HPLC workstation. Analytical HPLC runs were performed on Alltech Prosphere C4 or C8 and Adsorbosphere XL C18 columns (250 × 4.6 mm, pore size 300 Å , particle size: 5 lm) or on a Merck LiChroCART CN column (250 × 4.6 mm, pore size 100 Å , particle size: 5 lm) at a flow rate of 1.0 mL min −1 using a linear gradient of buffer B (0-100% in 25 min) in buffer A (buffer A: 0.1% TFA in H 2 O, buffer B: 0.1% TFA in CH 3 CN-H 2 O 95 : 5 v/v). Preparative HPLC runs were performed on an Alltech Prosphere C4 or C8 column (250 × 22 mm, pore size 300 Å , particle size: 10 lm), and semi-prep HPLC runs were performed on an Alltech Adsorbosphere XL C18 column (250 × 10 mm, pore size 300 Å , particle size: 10 lm) or on a Merck LiChroCART CN column (250 × 10 mm, pore size 100 Å , particle size: View Online chemical shifts are given in ppm (d) relative to 3-(trimethylsilyl)-1propanesulfonic acid sodium salt (0.00 ppm). Fourier transform infrared spectra (FTIR) were measured on a Bio-Rad FTS-25 spectrophotometer. Melting points were measured on a Büchi Schmelzpunktbestimmungsapparat and are uncorrected. Elemental analyses were done by Kolbe Mikroanalytisches Labor (Mülheim/Ruhr, Germany). R f values were determined by thin layer chromatography (TLC) on Merck precoated silica gel 60F254 plates. Spots were visualized by UV-quenching, ninhydrin or Cl 2 -TDM. 30 The 2-chlorotrityl chloride resin (Hecheng Science & Technology Company) was used in all solid phase syntheses. The coupling reagents 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) and benzotriazol-1-yloxy-tris-(dimethylamino)phosphonium hexafluorophosphate (BOP) were obtained from Biosolve. N-Hydroxybenzotriazole (HOBt) was from Advanced ChemTech and N a -9fluorenylmethyloxycarbonyl (Fmoc) amino acids were obtained from MultiSynTech. The side-chain protecting groups were chosen as tert-butyl for aspartic acid, tert-butyloxycarbonyl (Boc) for lysine and 2,2,4,6,7-pentamethyl-dihydrobenzofuran-5sulfonyl (Pbf) for arginine. Peptide-grade tert-butanol ( t BuOH), dichloromethane, N,N-dimethylformamide (DMF), 1,1,1,3,3,3hexafluoroisopropanol (HFIP), tert-butyl methylether (MTBE), N-methylpyrrolidone (NMP), and trifluoroacetic acid (TFA) and HPLC-grade acetonitrile were purchased from Biosolve. 2-(4,7,10-Tris(2-tert-butoxy-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1yl) acetic acid (DOTA(O t Bu) 3 ) was purchased from Macrocyclics. Piperidine, N,N-diisopropylethylamine (DIPEA), CuSO 4 and sodium ascorbate were obtained from Acros Organics. Triisopropylsilane (TIS) and HPLC-grade TFA were obtained from Merck. Triflic anhydride and propargylbromide were purchased from Aldrich.
Radiolabeling of the RGD dendrimers
Dendrimers 23 (25 lg, 20 nmol), 24 (25 lg, 13 nmol), and 25 (120 lg, 33 nmol) were radiolabeled by dissolving these compounds in 500 lL 0.5 M NH 4 OAc buffer, pH 6.0, containing 0.6 mg mL −1 gentisic acid. Then 22.2-37 MBq 111 InCl 3 was added to each of the reaction mixtures. The reaction mixtures were degassed and subsequently heated at 100 • C for 15 min. The 111 In-labeled dendrimers were further purified on a Waters C-18 SepPak cartridge (Milford, MA). After applying the sample on the methanol-activated cartridge, the cartridge was washed with 5 mL 25 mM NH 4 OAc and eluted with 25% CH 3 CN in 25 mM NH 4 OAc. The radiochemical purity was determined by reversedphase HPLC (HP 1100 series, Hewlett Packard, Palo Alto, CA, USA) using a Zorbax RX-C18 column (250 × 4.6 mm) eluted with a linear gradient of buffer B (8-20% in 25 min or 8-100% in 30 min in buffer A (buffer A: 25 mM NH 4 OAc, buffer B: CH 3 CN) at a flow rate of 1 mL min −1 . The radioactivity of the eluate was monitored using an in-line radiodetector (Flo-One Beta series, Radiomatic, Meriden, CT, USA).
Solid phase a V b 3 binding assay
The affinity of the DOTA-conjugated monovalent 23, divalent 24 and tetravalent 25 RGD dendrimers for the a v b 3 integrin was determined using a solid-phase competitive binding assay. 111 In-labeled DOTA-Glu-(c[RGDfK]) 2 (3 MBq lg −1 ) was prepared as described above and was used as the tracer in the assay. Microtiter 96-well vinyl assay plates (Corning B.V., Schiphol-Rijk, The Netherlands) were coated with 100 lL/well of a solution of purified human integrin a v b 3 (150 ng mL −1 ) in Triton X-100 Formulation (Chemicon International, Temecula, CA, USA) in coating buffer pH 7.4, 150 mM NaCl, 1 mM CaCl 2 , 0.5 mM MgCl 2 and 1 mM MnCl 2 ) for 17 h at 4 • C. The plates were washed twice with binding buffer (0.1% bovine serum albumin (BSA) in coating buffer). The wells were blocked for 2 h with 200 lL blocking buffer (1% BSA in coating buffer). The plates were washed twice with binding buffer. Then 100 lL binding buffer containing 11.1 kBq of 111 In-DOTA-Glu- (c[RGDfK] ) 2 and appropriate dilutions of non-labeled monovalent 23, divalent 24 and tetravalent 25 RGD dendrimers in binding buffer were incubated in the wells at 37 • C for 1 h. After incubation, the plates were washed three times with binding buffer. The retained radioactivity in each well was determined in a c-counter (1480 Wizard, Wallac, Turku, Finland) . The IC 50 values of the RGD dendrimers were calculated by nonlinear regression using GraphPad Prism (GraphPad Prism 4.0 Software, San Diego, CA, USA). Each data point represents the average of three individual determinations.
Biodistribution studies
In the right flank of 6-8 weeks old female nude BALB/c mice, 0.2 mL of a cell suspension of 8.5 × 10 6 cells/mL SK-RC-52 cells was injected subcutaneously (s.c.). Two weeks after inoculation of the tumor cells, mice were randomly divided into three groups. The mice were injected with 0.25-0.29 MBq of the 111 In-labeled dendrimers 23, 24, or 25 via a tail vein. The mice were euthanized by CO 2 asphyxiation, 2 and 24 h postinjection (p.i.) (2-5 mice/group). Blood, tumor, and the major organs and tissues were collected, weighed, and counted in a c-counter. The percentage injected dose per gram (%ID/g) was determined for each sample. To investigate whether the uptake of each of the three RGD dendrimers is a v b 3 -mediated, a separate group of mice was co-injected with an excess (50 lg) of non-radiolabeled DOTA-Glu- (c[RGDfK] ) 2 to saturate all the a v b 3 integrin receptors.
Statistical analysis
All mean values are given ± standard deviation (S.D.). Statistical analysis was performed using the One-way Analysis of Variance. Tukey corrections for multiple comparisons were applied. The level of significance was set at P < 0.05.
(3 × 20 mL), 1 N KHSO 4 (3 × 20 mL), H 2 O (3 × 20 mL), 5% NaHCO 3 (3 × 20 mL) and brine (3 × 20 mL), dried (Na 2 SO 4 ) and evaporated to dryness. The residue was purified by column chromatography (eluents: EtOAc-hexane 1 : 1 v/v) and was obtained as a white solid with 98% yield (1.38 g). Mp: 118-121 • C; R f (EtOAc-hexane 1 : 1 v/v): 0.20; 1 H NMR (CDCl 3 ) d: 1.42 (s, 9H, (CH 3 ) 3 Boc), 2.54 (s, 1H, CH), 3.38 (m, 2H, ∼NH-CH 2 -CH 2 ∼), 3.54 (m, 2H, ∼CH 2 -CH 2 -NH∼), 4.70 (s, 2H, ∼O-CH 2 ), 5.35 (m, 1H, NH urethane), 7.10-7.47 (broad m, 5H, arom H/NH amide); 13 C NMR (CDCl 3 ) d: 28.3, 39.9, 41.7, 55.8, 75.7, 78.1, 79.7, 113.4, 118.3, 119.8, 129.4, 135.6, 157.3, 157.6, 167.5 Butyl-2-(3,5-bis(prop-2-ynyloxy)benzamido) ethylcarbamate (12) . This compound was synthesized using acid 5 (506 mg, 2.20 mmol) and amine 10 (352 mg, 2.20 mmol) as described for 11. Compound 12 was obtained in 96% yield (760 mg) after column chromatography with EtOAc-hexane 8 : 2 v/v as eluents. Mp: 128-134 • C; R f (EtOAc-hexane 7 : 3 v/v): 0.31; 1 H NMR (CDCl 3 ) d: 1.42 (s, 9H, (CH 3 ) 3 Boc), 2.55 (s, 2H, CH), 3.37 (m, 2H, ∼NH-CH 2 -CH 2 ∼), 3.52 (m, 2H, ∼CH 2 -CH 2 -NH∼), 4.68 (s, 4H, ∼O-CH 2 ), 5.30 (m, 1H, NH urethane), 6.72 (s, 1H, arom H4), 7.06 (s, 2H, arom H2/H6), 7.44 (m, 1H, NH amide); 13 C NMR (125 MHz, CDCl 3 ) d: 28.3, 40.0, 41.7, 56.0, 75.9, 78.0, 79.8, 105.5, 106.6, 136.4, 157.3, 158.6, 167.2 5 C 64.50, H 6.50, N 7 .52 found C 63.61, H 6.21, N 7.05%. Butyl-2,2 ,2 -(10-(2-oxo-2-(2-(3-(prop-2-ynyloxy) 1,4,7,10-tetraazacyclododecane-1,4,7 -triyl)triacetate (13). To a solution of compound 11 (100 mg, 0.31 mmol) in CH 2 Cl 2 (5 mL), TFA (5 mL) was added to remove the Boc protecting group. After 1 h of stirring at room temperature, the volatiles were removed by evaporation and the residue was coevaporated with CH 2 Cl 2 to remove any residual TFA. The obtained solid was used without further purification. Then, the TFA-salt was dissolved in CH 2 Cl 2 (10 mL) and 2- (4,7,10-tris(2tert-butoxy-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl) acetic acid (DOTA(O t Bu) 3 ; 177 mg, 0.31 mmol), BOP (137 mg, 0.31 mmol) followed by DIPEA (220 lL, 1.24 mmol, 4 equiv) were added and the obtained reaction mixture was stirred for 16 h at room temperature. Subsequently, the solvent was removed by evaporation and the residue was redissolved in EtOAc (50 mL) and this solution was washed with H 2 O (3 × 20 mL), 1 N KHSO 4 (3 × 20 mL), H 2 O (3 × 20 mL), 5% NaHCO 3 (3 × 20 mL), brine (3 × 20 mL) and dried (Na 2 SO 4 ). Finally, the solvent was evaporated in vacuo after which 13 was obtained as a pale yellow oil with 94% yield (227 mg). R f (CH 2 Cl 2 -MeOH 9 : 1 v/v): 0.49; R t : 18.10 min (C8); 1 H NMR (CDCl 3 ) d: 1.42 (s, 27H, (CH 3 ) 3 t Bu), 2.20-3.70 (broad s, 28H, CH 2 DOTA (24H)/∼NH-CH 2 -CH 2 -NH∼(4H)), 2.52 (s, 1H, CH), 4.75 (s, 2H, ∼O-CH 2 ), 6.85 (m, 1H, NH), 7.08 (m, 1H, arom H), 7.25-7.32 (m, 2H, arom H), 7.51 (m, 2H , arom H/NH); 13 C NMR (CDCl 3 ) d: 27.9, 39.6, 39.7, 55.6, 55.8, 56.0, 75.5, 78.4, 81.8, 112.9, 118.9, 120.3, 129.6, 135.5, 157.6, 167.4, 172.0, 172.4; MS analysis: calcd for C 40 Butyl-2,2 ,2 -(10-(2-(2-(3,5-bis(prop-2-ynyloxy) benzamido)ethylamino)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7triyl)triacetate (14). This compound was synthesized as described for 13 starting from 12 (107 mg, 0.30 mmol). Compound 14 was obtained as a yellowish solid with nearly quantitative yield (250 mg). Mp: 74-84 • C; R f (CHCl 3 -MeOH-AcOH 95 : 20 : 3 v/v/v): 0.45; R t : 18.70 min (C8); 1 H NMR (CDCl 3 ) d: 1.43 (s, 27H, (CH 3 ) 3 t Bu), 2.04-3.70 (broad s, 28H, CH 2 DOTA (24H)/∼NH-CH 2 -CH 2 -NH∼(4H)), 2.52 (s, 2H, CH), 4.73 (s, 4H, ∼O-CH 2 ), 6.73 (m, 2H, arom H4/NH), 7.10 (s, 2H, arom H2/H6), 7.11 (m, 1H, NH) ; 13 C NMR (CDCl 3 ) d: 27.9, 39.6, 50.0*, 55.6, 55.8, 56.2, 75.6, 78.4, 81.9, 106.4, 106.5, 136.4, 158.7, 167.2, 172.0, 172.4 (*broad 4 C 51.58, H 6.64, N 8.39 found C 52.05, H 6.54, N 8 .04%. -2-(3,5-bis(2-(3,5-bis(prop-2-ynyloxy) 8.44 (m, 1H, NH amide), 8.68 (m, 2H, NH amide) ; 13 C NMR (DMSO-d 6 ) d: 28.0, 39.2, 55.9, 75.8, 75.9, 77.8, 79.6, 104.7, 105.4, 105.9, 106.7, 135.9, 136.1, 157.2, 158.5, 159.5, 167.7, 167.8, 168.0, 168. N 4 O 11 C 65.50, H 5.75, N 6.94 found C 65.28, H 5.71 , N 6.80%. Butyl-2,2 ,2 -(10-(2-(2-(3,5-bis(2-(3,5-bis(prop-2-ynyloxy) benzamido)ethoxy)benzamido)ethylamino)-2-oxyethyl)-1,4,7,10tetraazacyclododecane-1,4,7-triyl)triacetate (16) . Compound 16 was synthesized as described for 13 starting from 15 (242 mg, 0.30 mmol). After workup, the crude product was purified by column chromatography (eluents DCM-MeOH 98 : 2 v/v → DCM-MeOH 9 : 1 v/v) to yield a white solid (227 mg, 60% 28.0, 38.8, 39.3, 39.7, 55.7, 55.9, 56.2, 66.5, 75.8, 76.0, 78.3, 82.0, 106.0, 106.3, 106.5, 106.7, 136.3, 136.8, 158.6, 159.4, 166.7, 166.9, 171.5, 172.3 General procedure for the microwave-assisted click reaction. 22 The alkyne (1 equiv) and the azide (1.3 equiv per arm) were dissolved in DMF-H 2 O. To this solution, CuSO 4 ·5H 2 O (0.05 equiv) and Na-ascorbate (0.50 equiv) were added. The reaction mixture was placed in a microwave reactor and irradiated during 10-30 min at 100 • C. The cycloaddition was monitored on TLC and LC-MS for completion of the reaction.
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DOTA-conjugated monovalent cyclo[RGDfK]
peptide dendrimer (23). Alkyne 13 (5.5 mg, 7.1 lmol) and azido peptide 19 (6.0 mg, 8.1 lmol, 1.1 equiv) were dissolved in DMF (500 lL) and 0.05 M Na-ascorbate (72 lL, 3.6 lmol, 0.50 equiv) followed by 6 mM CuSO 4 ·5H 2 O (60 lL, 0.36 lmol, 0.05 equiv) were added. The reaction mixture was placed in the microwave reactor and irradiated for 3 × 5 min at 100 • C. Then, the solvents were removed under reduced pressure and the residue was dissolved in tert-BuOH-H 2 O 1 : 1 v/v and lyophilized. The obtained fluffy solid was dissolved in TFA-H 2 O (1 mL; 95 : 5 v/v) and stirred for 4 h at room temperature. Subsequently, the reaction mixture was concentrated in vacuo and the residue was redissolved in tert-BuOH-H 2 O 1 : 1 v/v, lyophilized and purified by semi-prep HPLC (C18) to give compound 23 in 13% yield (1.1 mg). DOTA-conjugated divalent cyclo[RGDfK] peptide dendrimer (24). 28 Alkyne 14 (4.9 mg, 5.9 lmol) and azido peptide 19 (11 mg, 14.8 lmol, 1.3 equiv) were dissolved in DMF-2,6-lutidine (1 mL, 7 : 3 v/v) and to this solution the following reagents were subsequently added: CuOAc (1.8 mg, 14.7 lmol, 2.5 equiv), Naascorbate (5.9 mg, 29.8 lmol, 5.1 equiv) and DIPEA (9.8 lL, 7.1 lmol, 1.2 equiv). The obtained reaction mixture was heated by microwave irradiation to 100 • C for 3 × 5 min. Then, the solvents were removed under reduced pressure and the residue was dissolved in tert-BuOH-H 2 O 1 : 1 v/v and lyophilized. The obtained fluffy solid was dissolved in TFA-H 2 O (1 mL; 95 : 5 v/v) and stirred for 4 h at room temperature. Subsequently, the reaction mixture was concentrated in vacuo and the residue was redissolved in tert-BuOH-H 2 O 1 : 1, lyophilized and purified by semi-prep HPLC (C18) to obtain compound 24 in 11% yield (1.3 mg). R t : 12.1 min (C18); MS analysis: calcd for C 85 H 120 N 28 O 24 , 1918 .067 (M ave ), found MALDI-TOF 1918.431 [M + H] ave + . (25) . Alkyne 16 (3.8 mg, 3 .0 lmol) and azido peptide 19 (11 mg, 14.8 lmol, 1.2 equiv) were dissolved in DMF (500 lL) and to this solution, 0.05 M Na-ascorbate (30 lL, 1.5 lmol, 0.50 equiv) followed by 6 mM CuSO 4 ·5H 2 O (25 lL, 0.15 lmol, 0.05 equiv) were added. The obtained reaction mixture was heated by microwave irradiation to 100 • C for 2 × 5 min. Then, the solvents were removed under reduced pressure and the residue was dissolved in tert-BuOH-H 2 O 1 : 1 v/v and lyophilized. The obtained fluffy solid was dissolved in TFA-H 2 O (1 mL; 95 : 5 v/v) and stirred for 4 h at room temperature. Subsequently, the reaction mixture was concentrated in vacuo and the residue was redissolved in tert-BuOH-H 2 O 1 : 1 v/v, lyophilized and purified by semiprep HPLC (C18) to give compound 25 in 36% yield (3.9 mg). R t : 11.6 min (C18); MS analysis: calcd for C 163 H 220 N 52 O 44 , 3611.873 (M ave ), found MALDI-TOF 3612.646 [M + H] ave + .
DOTA-conjugated tetravalent cyclo[RGDfK] peptide dendrimer
